Idorsia

Idorsia is a leading Swiss biopharmaceutical company specialized in the discovery, development, and commercialization of small-molecule therapeutics. The company was founded in 2017 as a spin-off from Actelion following its $30 billion acquisition by Johnson & Johnson. Idorsia inherited a robust pipeline of innovative compounds and a world-class drug discovery engine, positioning it as a major player in the European biotech landscape. The company focuses on a wide range of therapeutic areas, including central nervous system (CNS) disorders, cardiovascular diseases, immunology, and orphan diseases. Idorsia has successfully transitioned into a commercial-stage entity with the launch of Quviviq for insomnia and the recent FDA approval of Tryvio for resistant hypertension. Despite facing recent financial challenges and debt restructuring, the company has secured strategic partnerships with global firms like Viatris to advance its late-stage pipeline.